Clinical Trial Update: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) [Phase 1]

View source ↗

Summary

Amgen's Phase 1 study is assessing safety, tolerability, and pharmacokinetics of Tarlatamab in adults with small cell lung cancer, with the trial currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Small Cell Lung Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING